Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Efficacy & tolerability of available TKI therapies in CML & managing TKI resistance

Jeffrey Lipton • 26 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia Asciminib Bosutinib Ponatinib

Jeffrey Lipton, PhD, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, highlights the different tyrosine kinase inhibitors (TKI) available for the treatment of chronic myeloid leukemia (CML), commenting on their efficacy and toxicity, and discussing the management of CML in the third-line setting. Prof. Lipton also outlines novel TKIs under investigation for patients who are resistant to available TKIs. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jeffrey Lipton

2:45
Understanding the cause of TKI resistance to improve management strategies in CML
Jeffrey Lipton • 26 Oct 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals